These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36983419)
41. Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination. Uchiyama Y; Fukasawa H; Ishino Y; Nakagami D; Kaneko M; Yasuda H; Furuya R BMC Nephrol; 2022 Jun; 23(1):216. PubMed ID: 35729514 [TBL] [Abstract][Full Text] [Related]
42. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases. Udaondo C; Cámara C; Miguel Berenguel L; Alcobendas Rueda R; Muñoz Gómez C; Millán Longo C; Díaz-Delgado B; Falces-Romero I; Díaz Almirón M; Ochando J; Méndez-Echevarría A; Remesal Camba A; Calvo C Pediatr Rheumatol Online J; 2022 Aug; 20(1):64. PubMed ID: 35964130 [TBL] [Abstract][Full Text] [Related]
43. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021. Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630 [TBL] [Abstract][Full Text] [Related]
44. IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three cases. Yokote S; Ueda H; Shimizu A; Okabe M; Yamamoto K; Tsuboi N; Yokoo T CEN Case Rep; 2022 Nov; 11(4):499-505. PubMed ID: 35562631 [TBL] [Abstract][Full Text] [Related]
45. Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity. Chighizola CB; Suardi I; Carrea G; Argolini L; Gattinara M; Marino A; Pontikaki I; Caporali R; Gerosa M Rheumatology (Oxford); 2023 Sep; 62(9):3146-3150. PubMed ID: 36702464 [TBL] [Abstract][Full Text] [Related]
46. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
47. Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia. Alghamdi A; Alsanea N; Alraey M; Joseph M; Aboud M; Almangour T; Alharbi W; Alhumidan H; Alanizi A; Al-Jedai A Ann Saudi Med; 2022; 42(4):223-228. PubMed ID: 35933607 [TBL] [Abstract][Full Text] [Related]
48. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. Beckley M; Olson AK; Portman MA JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521 [TBL] [Abstract][Full Text] [Related]
49. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A; Front Immunol; 2022; 13():868915. PubMed ID: 35432335 [TBL] [Abstract][Full Text] [Related]
50. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954 [TBL] [Abstract][Full Text] [Related]
52. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468 [TBL] [Abstract][Full Text] [Related]
53. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048 [TBL] [Abstract][Full Text] [Related]
54. Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination. Young BE; Seppo AE; Diaz N; Rosen-Carole C; Nowak-Wegrzyn A; Cruz Vasquez JM; Ferri-Huerta R; Nguyen-Contant P; Fitzgerald T; Sangster MY; Topham DJ; Järvinen KM JAMA Pediatr; 2022 Feb; 176(2):159-168. PubMed ID: 34757387 [TBL] [Abstract][Full Text] [Related]
55. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. Smith JB; Gonzales EG; Li BH; Langer-Gould A JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740 [TBL] [Abstract][Full Text] [Related]